Murgiano et al. make a compelling case for studying iconicity in multimodal face-to-face interaction, but they appear ambivalent about the importance of iconicity at the level of the linguistic system. We argue that, rather than decreasing over time, iconicity is a stable property of languages. Understanding how and why this is so is critical to building a complete real-world theory of language that bridges the situated context of language use with language as an evolving symbolic system. An important point for future research is to examine the interface between iconic prosody and the latent iconic features of words and signs that are frozen in the linguistic system.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396115 | PMC |
| http://dx.doi.org/10.5334/joc.166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024.
Acta Pharmacol Sin
January 2025
Department of Medical Microbiology & Parasitology, MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University Shanghai Medical College, Shanghai, 200032, China.
Metabolic dysfunction-associated steatotic liver disease (MASLD) covers a broad spectrum of profile from simple fatty liver, evolving to metabolic dysfunction-associated steatohepatitis (MASH), to hepatic fibrosis, further progressing to cirrhosis and hepatocellular carcinoma (HCC). MASLD has become a prevalent disease with 25% in average over the world. MASH is an active stage, and requires pharmacological intervention when there is necroptotic damage with fibrotic progression.
View Article and Find Full Text PDFPsoriasis severity in moderate to severe psoriatic Greek patients routinely treated with systemic treatment: a cross-sectional and retrospective chart review study (CRYSTAL-Greece).
J Dermatolog Treat
December 2025
2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece.
Objective: To characterize the systemic treatment patterns and current state of moderate-to-severe psoriasis patients in real-world settings in Greece.
Methods: CRYSTAL-Greece was a multicenter, cross-sectional and retrospective chart review study assessing Psoriasis Area and Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5-Dimensions 5-Levels (EQ-5D-5L). Eligible patients were consented adults (18-75 years old) on continuous treatment with any approved systemic therapy regimen for ≥24 weeks.
Prospective Validation of CAR-HEMATOTOX and a simplified version predict Survival in Patients with Large B-Cell Lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study.
Transplant Cell Ther
January 2025
Chair of Hematology, University of Milan; Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.
Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in non-relapse mortality, largely driven by infections, leading to the development of the CAR-HEMATOTOX (HT) score for predicting neutropenia. The European scientific community (EHA/EBMT) later reached a consensus, defining a new entity: immune effector cell-associated hematotoxicity (ICAHT).
View Article and Find Full Text PDFReal-world implementation of pain science education and barriers to use in private practice physiotherapy settings: an Australia-wide cross-sectional survey.
Pain
January 2025
Innovation, IMPlementation And Clinical Translation (IIMPACT) in Health, University of South Australia, Kaurna Country, Adelaide, Australia.
Physiotherapists are critically positioned to integrate education into patient care, including pain science education (PSE) to enhance management and outcomes. Anecdotally, many physiotherapists report difficulty providing PSE in private practice settings. Here, we aimed to explore current PSE use, knowledge, and barriers to implementation.
View Article and Find Full Text PDFReal-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review.
Reumatismo
January 2025
Unit of Dermatology, Department of Medicine and Aging Science, G. d'Annunzio University, Chieti.
Objective: Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies.
Methods: An observational study was conducted on adult subjects with PsA and comorbidities, treated with secukinumab after prior therapy with conventional disease-modifying anti-rheumatic drugs or biological agents that were discontinued due to lack of efficacy or adverse drug reactions. Patients were followed up with clinical visits at 3, 6, 9, and 12 months and evaluated for disease activity, pain, and quality of life, with respect to values recorded at baseline.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!